RCT of Mind-body in Long COVID and Myalgic Encephalomyelitis

NCT ID: NCT06933173

Last Updated: 2025-07-16

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

200 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-10

Study Completion Date

2027-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

We are studying the effect of a mind-body treatment for people with Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) with or without Long COVID (LC). Our team recognizes that ME/CFS and Long COVID are serious, debilitating, biomedical conditions.

ME/CFS can affect many different parts of the body, such as the nervous system, immune system, and metabolism. It is hypothesized that central sensitization (i.e., when nerves get too excited) may influence these complex conditions and may make symptoms worse.

This study explores a mind-body program called the Dynamic Neural Retraining System™, or DNRS™.

Mind-body interventions (MBIs) focus on how the brain, mind, body, and behaviour interact to improve health and well-being. These techniques help people become more aware of themselves, take better care of their health, and boost mood, quality of life, and coping skills. MBIs use the brain's ability to change (neuroplasticity) by reinforcing certain thoughts, feelings, or behaviours that support changes in biology and function. MBIs may influence physical health by affecting how the brain and body communicate through chemicals such as hormones and neurotransmitters. Objective fMRI evidence shows that practising MBIs can change brain structure and function. This makes MBIs a potential good fit for people with chronic illnesses like ME/CFS and LC, which involve complex interactions between the brain, immune system, and hormones.

There is no rigorous peer-reviewed evidence that DNRS is effective. Our study will address this question using subjective and objective measurements in a multiple-methods wait-list randomized controlled trial.

The objectives of this study are to: 1) examine the effectiveness of the DNRS program for individuals diagnosed with ME/CFS with and without Long COVID, compared to a treatment-as-usual wait-list control group on a range of patient-reported outcomes including health-related quality of life, fatigue, pain, anxiety and depression and objective measures including daily steps, heart rate variability, and sleep; 2) quantify metabolic changes through untargeted serum metabolomics profiling, 3) determine if metabolomics screening can predict treatment responsiveness to DNRS; and 4) identify the microbial signatures of large bowel microbiota in Long COVID patients pre and post MBI.

A descriptive qualitative study will also be conducted in a sample of participants to learn more about their experiences during the trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Myalgic Encephalomyelitis/Chronic Fatigue Syndrome

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

DNRS intervention group

Group Type EXPERIMENTAL

Dynamic neural retraining system

Intervention Type OTHER

Description: The DNRS program includes the following components: 1) cognitive-behavioural therapy; 2) mindfulness-based cognitive restructuring; 3) emotional restructuring therapy; 4) neural linguistic programming; 5) incremental training; and 6) behaviour modification therapy. DNRS offered in this study includes a 14-hour online course followed by a 12-week online "LIVING DNRS" group support program. The 14-hour online course includes a variety of exercises, instructional videos, and a workbook. Upon completion, participants are offered a 12-week LIVING DNRS Group Support program which provides individuals with support in how to best implement DNRS into their daily lives with the help of a trained facilitator as well as peer support.

Wait-list control group

The waitlist control group will complete the experimental intervention after 4 months. During the waiting period, they will continue to receive usual care and will be asked to not participate in any other new treatments.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Dynamic neural retraining system

Description: The DNRS program includes the following components: 1) cognitive-behavioural therapy; 2) mindfulness-based cognitive restructuring; 3) emotional restructuring therapy; 4) neural linguistic programming; 5) incremental training; and 6) behaviour modification therapy. DNRS offered in this study includes a 14-hour online course followed by a 12-week online "LIVING DNRS" group support program. The 14-hour online course includes a variety of exercises, instructional videos, and a workbook. Upon completion, participants are offered a 12-week LIVING DNRS Group Support program which provides individuals with support in how to best implement DNRS into their daily lives with the help of a trained facilitator as well as peer support.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Age 18 years or older;
* Individuals diagnosed with ME/CFS, according to the Institute of Medicine (2015) criteria, for more than six months.

Exclusion Criteria

Individuals who: 1) are too ill to participate; 2) lack reliable internet; 3) cannot communicate in English; 4) Presently have or ever had inflammatory bowel disease; and/or 5) Have been prescribed or used an oral or systemic (infusion) antibiotic in the past one month-;; 6) are participating in a concurrent study; 7) are participating in a concurrent mind-body intervention during the study period including

* Art Therapy
* Autogenic training
* Biofeedback/neurofeedback
* Breathing exercise
* Cognitive restructuring
* Dynamic Neural Retraining System
* Emotional Freedom Techniques (EFT)
* Eye movement desensitization and reprocessing (EMDR)
* Guided imagery
* Hypnotherapy/self-hypnosis
* Meditation (mindfulness, mantra, guided, transcendental)
* Mindfulness-based cognitive therapy (MBCT)
* Mindfulness-based Stress Reduction (MBSR)
* Music therapy
* Neurolinguistic programming
* Psychological flexibility
* Qigong
* Relaxation therapy (relaxation response, progressive muscle relaxation)
* Tai Chi
* Visualization
* Yoga and/or starting any other new treatment during the study period, including any mind-body therapy, psychotherapy, prescription medication, over-the-counter medication, etc; 8) have any active medical condition (untreated/uncontrolled) that may explain the presence of fatigue including:
* untreated hypothyroidism (including Hashimoto's disease)
* hyperthyroidism
* diabetes mellitus
* iron deficiency anemia
* other treatable anemia
* iron overload syndrome
* adrenal insufficiency
* Cushing's syndrome
* anorexia nervosa
* iatrogenic conditions such as side effects or interactions of medication(s) or supplements

• Rheumatological disorders:
* rheumatoid arthritis
* lupus
* polymyositis
* polymyalgia rheumatica
* Sjogren's Syndrome
* Ehlers Danlos Syndromes \[Hypermobility type\]

• Other heritable disorders of connective tissue:
* Marfan syndrome
* Stickler syndrome etc.

* Multiple sclerosis
* Celiac disease
* Note: Patients with celiac disease can present without gastrointestinal symptoms

• Immune disorders
* such as HIV/AIDS

• Sleep disorders
* including obstructive sleep apnea

• Prior illnesses may relapse or may not have completely resolved during treatment.
* Examples are certain malignancies
* leukemia
* infectious diseases such as tuberculosis and chronic hepatitis

• Active primary psychiatric disorders
* eating disorders
* alcohol
* substance use disorder
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

College of Physicians and Surgeons of Alberta

UNKNOWN

Sponsor Role collaborator

University of Alberta

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Sunita Vohra, MD MSc FRCPC FCAHS

Role: PRINCIPAL_INVESTIGATOR

University of Alberta

Eleanor Stein, MD FRCPC

Role: PRINCIPAL_INVESTIGATOR

University of Calgary

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Peter Lougheed Hospital

Calgary, Alberta, Canada

Site Status RECRUITING

University of Alberta Hospital/Kaye Edmonton Clinic

Edmonton, Alberta, Canada

Site Status RECRUITING

Women's College Hospital

Toronto, Ontario, Canada

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Canada

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

MILES RCT team

Role: CONTACT

780-680-8907

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Elizabeth MacKay, MD

Role: primary

MILES RCT team

Role: primary

780-680-8907

Sunita Vohra

Role: backup

Riina Bray

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Pro00138185

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Use of a Monitor in ME/CFS
NCT01908036 UNKNOWN
Inflammatory Response to OMT
NCT06820684 COMPLETED NA
Skeletal Muscle in PASC and ME/CFS Patients
NCT05225688 ACTIVE_NOT_RECRUITING
Multi-Center Registry for ME/CFS
NCT05778006 RECRUITING
Multiple Areas of Pain (MAP)
NCT01583894 COMPLETED